Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at MD Anderson Cancer Center

Sites in Houston, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
2390
Shown on this page
12
Current sort
Recently updated
Campus scope
MD Anderson Cancer Center, Houston, TX
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within MD Anderson Cancer Center, Houston, TX. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 169–180 of 2,390 matching trials with a site at MD Anderson Cancer Center, Houston, TX.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334
Site status not listed — check the official record
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Endocrine Therapy (ET)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry

NCT06840288
Status at this site: Recruiting
View directory record Official record
Conditions
Thoracic Tumors
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Timeline
2025 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

NCT07195916
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies
Interventions
INCA036873
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

NCT02474160
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
National Cancer Institute LAO
Other
Eligibility
2 Months and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
139
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Arroyo Grande, California + 94 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

NCT05836571
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute LAO
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
26
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805
Status at this site: Recruiting
View directory record Official record
Conditions
Primary Myelofibrosis
Interventions
LY5830966
Drug
Lead sponsor
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Palo Alto, California • Tampa, Florida • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289
Status at this site: Recruiting
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
30
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Active, not recruiting Phase 2 Interventional

EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement

NCT05044468
Site status not listed — check the official record
View directory record Official record
Conditions
Malignant Pleural Neoplasm
Interventions
Lidocaine, Liposomal Bupivacaine, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Active, not recruiting Phase 2 Interventional

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

NCT02754752
Site status not listed — check the official record
View directory record Official record
Conditions
Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Electroacupuncture Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT
Recruiting Not applicable Interventional

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

NCT02918474
Status at this site: Recruiting
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Sporadic Breast Carcinoma
Interventions
Decision Aid, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:32 AM EDT

About this MD Anderson Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list MD Anderson Cancer Center in Houston, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by M.D. Anderson Cancer Center at any site, browse by condition, or browse by U.S. city.